NCT04248283 Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
| NCT ID | NCT04248283 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Uromedica |
| Condition | Urinary Incontinence |
| Study Type | INTERVENTIONAL |
| Enrollment | 167 participants |
| Start Date | 2021-01-26 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 167 participants in total. It began in 2021-01-26 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
Eligibility Criteria
Inclusion Criteria: 1. Female at least 22 years old 2. Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency 3. Provocative pad weight of greater than 11.0 grams 4. Candidate for surgical intervention 5. Negative urinalysis 6. Normal cystourethroscopy 7. Failed at least 6 months of previous treatment(s) for stress urinary incontinence (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note: patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension, sling, or urethral bulking agent) 8. Willing and able to sign informed consent and comply with trial follow-up requirements Exclusion Criteria: 1. Pregnant or lactating 2. Life expectancy of less than 5 years 3. Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose over 130 mg/dL 4. Has auto-immune disease 5. Undergoing radiation therapy 6. Active urinary tract infection 7. Detrusor instability refractory to medication 8. Reduced bladder compliance as defined by a cystometrogram 9. Significant residual volume (greater than 100 ml) after voiding in which detrusor contraction is weak, when the bladder volume is greater than or equal to 250 ml 10. Has, had, or is suspected of having bladder cancer 11. History of bladder stones 12. Urethral stricture evidenced during cystourethroscopy 13. Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia 14. Has a diathesis, hemophilia, or a bleeding disorder 15. Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or higher 16. Had prior pelvic radiotherapy 17. Had a prior artificial urinary sphincter implanted 18. Has a neurogenic condition known to affect bladder/sphincter function
Contact & Investigator
Philip Johnson, PhD
STUDY DIRECTOR
Uromedica, Inc.
Frequently Asked Questions
Who can join the NCT04248283 clinical trial?
This trial is open to female participants only, aged 22 Years or older, studying Urinary Incontinence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04248283 currently recruiting?
Yes, NCT04248283 is actively recruiting participants. Contact the research team at USLDR@COLOPLAST.COM for enrollment information.
Where is the NCT04248283 trial being conducted?
This trial is being conducted at Denver, United States, Omaha, United States, Marseille, France, Nantes, France and 1 additional location.
Who is sponsoring the NCT04248283 clinical trial?
NCT04248283 is sponsored by Uromedica. The principal investigator is Philip Johnson, PhD at Uromedica, Inc.. The trial plans to enroll 167 participants.